{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:21:51Z","timestamp":1758633711024,"version":"3.41.0"},"publisher-location":"Cham","reference-count":65,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319557793"},{"type":"electronic","value":"9783319557809"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-55780-9_15","type":"book-chapter","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T12:13:52Z","timestamp":1501244032000},"page":"157-172","source":"Crossref","is-referenced-by-count":10,"title":["Hereditary Tyrosinemia Type 1 in Turkey"],"prefix":"10.1007","author":[{"given":"Ayse Cigdem","family":"Aktuglu-Zeybek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertugrul","family":"Kiykim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Serif","family":"Cansever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,29]]},"reference":[{"key":"15_CR64","doi-asserted-by":"crossref","unstructured":"Aktuglu Zeybek AC, Kiykim E, Soyucen E, Cansever S, Altay S, Zubarioglu T, Erkan T, Aydin A (2015) Hereditary tyrosinemia type 1 in Turkey: twenty-year single-center experience. Pediatrics International 57(2):281\u2013289","DOI":"10.1111\/ped.12503"},{"issue":"1","key":"15_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10545-005-5085-4","volume":"28","author":"N Andr\u00e9","year":"2005","unstructured":"Andr\u00e9 N, Roquelaure B, Jubin V et al (2005) Successful treatment of severe cardiomyopathy with NTBC in a child withtyrosinaemia type I. J Inherit Metab Dis 28(1):103\u2013106","journal-title":"J Inherit Metab Dis"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/8904_2014_363","volume":"19","author":"F Angileri","year":"2015","unstructured":"Angileri F, Bergeron A, Morrow G et al (2015) Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep 19:43\u201358","journal-title":"JIMD Rep"},{"issue":"1","key":"15_CR3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10545-006-0203-5","volume":"29","author":"N Arora","year":"2006","unstructured":"Arora N, Stumper O, Wright J et\u00a0al (2006) Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 29(1):54\u201357","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"15_CR4","first-page":"329","volume":"13","author":"A Bahador","year":"2015","unstructured":"Bahador A, Dehghani SM, Geramizadeh B et al (2015) Liver transplant for children with hepatocellular carcinoma and hereditary tyrosinemia type 1. Exp Clin Transplant 13(4):329\u2013332","journal-title":"Exp Clin Transplant"},{"issue":"2","key":"15_CR5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10545-005-5517-1","volume":"28","author":"U Baumann","year":"2005","unstructured":"Baumann U, Preece MA, Green A et al (2005) J Inherit Metab Dis 28(2):131\u2013135","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"15_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12288-011-0115-x","volume":"28","author":"A Bay","year":"2012","unstructured":"Bay A, Karaoglu O, Sivasli E et al (2012) An infant with prolonged circumcision bleeding and unexplained coagulopathy. Indian J Hematol Blood Transf 28(3):181\u2013183","journal-title":"Indian J Hematol Blood Transf"},{"key":"15_CR7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jpeds.2013.10.001","volume":"164","author":"F Bendadi","year":"2014","unstructured":"Bendadi F, de Koning TJ, Visser G et al (2014) Impaired cognitive functioning in patients with tyrosinemia type 1 receiving nitisinone. J Pediatr 164:398\u2013401","journal-title":"J Pediatr"},{"issue":"1","key":"15_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1098-1004(1998)12:1<19::AID-HUMU3>3.0.CO;2-3","volume":"12","author":"AJ Bergman","year":"1998","unstructured":"Bergman AJ, van den Berg IE, Brink W et al (1998) Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hum Mutat 12(1):19\u201326","journal-title":"Hum Mutat"},{"key":"15_CR9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/humu.23047","volume":"37","author":"PR Blackburn","year":"2016","unstructured":"Blackburn PR, Hickey RD, Nace RA et al (2016) Silent tyrosinemia type i without elevated tyrosine or succinylacetone associated with liver cirrhosis and hepatocellular carcinoma. Hum Mutat 37:1097\u20131105. [Epub ahead of print]","journal-title":"Hum Mutat"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-1172-4-28","volume":"4","author":"D Cassiman","year":"2009","unstructured":"Cassiman D, Zeevaert R, Holme E et al (2009) A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report. Orphanet J Rare Dis 4:28","journal-title":"Orphanet J Rare Dis"},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-642-15720-2_18","volume-title":"Inborn metabolic diseases, diagnosis and treatment","author":"A Chakrapani","year":"2012","unstructured":"Chakrapani A, Gissen P, McKierrnan P (2012) Disorders of tyrosine metabolism. In: Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, diagnosis and treatment, 5th edn. Springer, Heidelgerg, pp 265\u2013276","edition":"5th"},{"issue":"5","key":"15_CR12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF01799947","volume":"14","author":"T Coskun","year":"1991","unstructured":"Coskun T, Ozalp I, Ko\u00e7ak N et al (1991) Type I hereditary tyrosinaemia: presentation of 11 cases. J Inherit Metab Dis 14(5):765\u2013770","journal-title":"J Inherit Metab Dis"},{"key":"15_CR13","unstructured":"Counce ML, Dalmau J, del Toro M et al (2011) Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 53(6):985\u2013989"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1469-8749.2011.04048.x","volume":"53","author":"C Laet De","year":"2011","unstructured":"De Laet C, Munoz VT, Jaeken J et\u00a0al (2011) Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol 53:962\u2013964","journal-title":"Dev Med Child Neurol"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cca.2010.12.028","volume":"412","author":"KS Dhillon","year":"2011","unstructured":"Dhillon KS, Bhandal AS, Aznar CP et al (2011) Improved tandem mass spectrometry (MS\/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process. Clin Chim Acta 412:873\u2013879","journal-title":"Clin Chim Acta"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/8904_2011_10","volume":"1","author":"A Dursun","year":"2011","unstructured":"Dursun A, Ozg\u00fcl RK, Sivri S et al (2011) Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease. JIMD Rep 1:17\u201321","journal-title":"JIMD Rep"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00431-009-1090-1","volume":"169","author":"H El-Karaksy","year":"2010","unstructured":"El-Karaksy H, Rashed M, El-Sayed R et al (2010) Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr 169:689\u2013693","journal-title":"Eur J Pediatr"},{"issue":"3","key":"15_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12519-011-0287-3","volume":"7","author":"H El-Karaksy","year":"2011","unstructured":"El-Karaksy H, Fahmy M, El-Raziky M et al (2011) Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases. World J Pediatr 7(3):224\u2013231","journal-title":"World J Pediatr"},{"key":"15_CR19","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/ICL.0000000000000187","volume":"43","author":"D Gulmez Sevim","year":"2015","unstructured":"Gulmez Sevim D, Gumus K, Cavanagh HD (2015) Corneal pseudodendritic lesions masquerading as herpetic keratitis in a patient with tyrosinemia type I. Eye Contact Lens 43:e7\u2013e9. [Epub ahead of print]","journal-title":"Eye Contact Lens"},{"key":"15_CR63","doi-asserted-by":"crossref","unstructured":"Haagen AAM, Duran M, (1987) Absence of increased succinylacetone in the urine of a child with hereditary tyrosinaemia type I. J Inherit Metab Dis 10 (S2):323\u2013325","DOI":"10.1007\/BF01811440"},{"key":"15_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10545-016-9949-6","volume":"39","author":"MA Hillgartner","year":"2016","unstructured":"Hillgartner MA, Coker SB, Koenig AE et al (2016) Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice. J Inherit Metab Dis 39:673\u2013682. [Epub ahead of print]","journal-title":"J Inherit Metab Dis"},{"key":"15_CR21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/0140-6736(92)92724-T","volume":"340","author":"E Holme","year":"1992","unstructured":"Holme E, Lindstedt S (1992) Neonatal screen for hereditary tyrosinemia type I. Lancet 340:850","journal-title":"Lancet"},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1005410820201","volume":"21","author":"E Holme","year":"1998","unstructured":"Holme E, Lindstedt S (1998) Tyrosinaemia type 1 and NTBC (2-(2-nitro- 4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21:507\u2013517","journal-title":"J Inherit Metab Dis"},{"key":"15_CR23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1089-3261(05)70142-2","volume":"4","author":"E Holme","year":"2000","unstructured":"Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805\u2013814. 34","journal-title":"Clin Liver Dis"},{"key":"15_CR24","doi-asserted-by":"crossref","unstructured":"Jenkins J (2002) Orphadin. Cited 30 June 2016. Available from URL: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21232lbl.pdf","DOI":"10.1145\/512526.512515"},{"key":"15_CR25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/hmg\/10.17.1741","volume":"10","author":"R Jorquera","year":"2001","unstructured":"Jorquera R, Tanguay RM (2001) Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 10:1741\u20131752","journal-title":"Hum Mol Genet"},{"key":"15_CR26","first-page":"501","volume":"41","author":"HS Kalkanoglu","year":"1999","unstructured":"Kalkanoglu HS, Coskun T (1999) Neurological crisis mimicking acute pancreatitis in tyrosinemia type I. Turk J Pediatr 41:501\u2013504. 38","journal-title":"Turk J Pediatr"},{"key":"15_CR65","doi-asserted-by":"crossref","unstructured":"Koelink CJL, van Hasselt P, van der Ploeg A, et al (2006) Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 89(4):310\u2013315","DOI":"10.1016\/j.ymgme.2006.07.009"},{"issue":"1","key":"15_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01804389","volume":"14","author":"EA Kvittingen","year":"1991","unstructured":"Kvittingen EA, Talseth T, Halvorsen S et al (1991) Renal failure in adult patients with hereditary tyrosinaemia type I. J Inherit Metab Dis 14(1):53\u201362","journal-title":"J Inherit Metab Dis"},{"key":"15_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","volume":"107","author":"J Larochelle","year":"2012","unstructured":"Larochelle J, Alvarez F, Bussi\u00e8res JF et al (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Qu\u00e9bec. Mol Genet Metab 107:49\u201354","journal-title":"Mol Genet Metab"},{"key":"15_CR29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","volume":"340","author":"S Lindstedt","year":"1992","unstructured":"Lindstedt S, Holme E, Lock EA et al (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813\u2013817","journal-title":"Lancet"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1023\/A:1005458703363","volume":"21","author":"EA Lock","year":"1998","unstructured":"Lock EA, Ellis MK, Gaskin P et al (1998) From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro- 4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 21:498\u2013506","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"15_CR31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","volume":"31","author":"A Masurel-Paulet","year":"2008","unstructured":"Masurel-Paulet A, Poggi-Bach J, Rolland MO et al (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31(1):81\u201387","journal-title":"J Inherit Metab Dis"},{"key":"15_CR32","first-page":"9","volume":"1","author":"S Mayorandan","year":"2014","unstructured":"Mayorandan S, Meyer U, Gokcay G et al (2014) Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 1:9. 107","journal-title":"Orphanet J Rare Dis"},{"key":"15_CR33","doi-asserted-by":"crossref","unstructured":"Mckiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinemia type 1. Drugs 66:743\u2013750","DOI":"10.2165\/00003495-200666060-00002"},{"issue":"8","key":"15_CR34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/archdischild-2014-306886","volume":"100","author":"PJ McKiernan","year":"2015","unstructured":"McKiernan PJ, Preece MA, Chakrapani A (2015) Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child 100(8):738\u2013741","journal-title":"Arch Dis Child"},{"key":"15_CR35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJM199002153220704","volume":"322","author":"G Mitchell","year":"1990","unstructured":"Mitchell G, Larochelle J, Lambert M et al (1990) Neurologic crisis in hereditary tyrosinemia. N Engl J Med 322:432\u2013437","journal-title":"N Engl J Med"},{"key":"15_CR36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1756-0500-6-362","volume":"6","author":"S Mohamed","year":"2013","unstructured":"Mohamed S, Kambal MA, Al Jurayyan NA et al (2013) Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes 6:362","journal-title":"BMC Res Notes"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ymgme.2011.02.017","volume":"103","author":"MA Morrissey","year":"2011","unstructured":"Morrissey MA, Sunny S, Fahim A et al (2011) Newborn screening for Tyr-I: two years\u2019 experience of the New York State program. Mol Genet Metab 103:191\u20132.22","journal-title":"Mol Genet Metab"},{"issue":"1","key":"15_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ped.12550","volume":"57","author":"K Nakamura","year":"2015","unstructured":"Nakamura K, Matsumoto S, Mitsubuchi H et al (2015) Diagnosis and treatment of hereditary tyrosinemia in Japan. Pediatr Int 57(1):37\u201340","journal-title":"Pediatr Int"},{"key":"15_CR39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s11011-016-9833-y","volume":"31","author":"N Onenli Mungan","year":"2016","unstructured":"Onenli Mungan N, Y\u0131ld\u0131zdas D, Kor D et al (2016) Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis 31:1181\u20131183. [Epub ahead of print]","journal-title":"Metab Brain Dis"},{"key":"15_CR40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/BF01799576","volume":"13","author":"I Ozalp","year":"1990","unstructured":"Ozalp I, Coskun T, Tokol S et al (1990) Inherited metabolic disorders in Turkey. J Inherit Metab Dis 13:732\u2013738","journal-title":"J Inherit Metab Dis"},{"key":"15_CR41","first-page":"96","volume":"18","author":"M Pohorecka","year":"2012","unstructured":"Pohorecka M, Biernacka M, Jakubowska-Winecka A et al (2012) Behavioral and intellectual functioning in patients with tyrosinemia type 1. Pediatr Endocrinol Diabetes Metab 18:96\u2013100","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"15_CR42","first-page":"2218","volume-title":"Tietz textbook of clinical chemistry and molecular diagnostics","author":"P Rinaldo","year":"2006","unstructured":"Rinaldo P, Hahn SH, Matern D (2006) Inborn errors of amino acid, organic acid, and fatty acid metabolism. In: Burtis CA, Ashwood ER, Bruns DE (eds) Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier, St. Louis, pp 2218\u20132219"},{"issue":"4","key":"15_CR43","first-page":"653","volume":"55","author":"H Rootwelt","year":"1994","unstructured":"Rootwelt H, Berger R, Gray G et al (1994) Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1. Am J Hum Genet 55(4):653\u2013658","journal-title":"Am J Hum Genet"},{"issue":"3","key":"15_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.0.CO;2-5","volume":"7","author":"H Rootwelt","year":"1996","unstructured":"Rootwelt H, Hoie K, Berger R et al (1996) Fumarylacetoacetase mutations in tyrosinaemia type I. Hum Mutat 7(3):239\u2013243","journal-title":"Hum Mutat"},{"key":"15_CR45","unstructured":"Roth KS (2007) Tyrosinemia (Emedicine Website). Cited 30 June 2016. Available from URL: http:\/\/www.emedicine.com\/ped\/TOPIC2339.HTM"},{"key":"15_CR46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","volume":"4","author":"P Russo","year":"2001","unstructured":"Russo P, Mitchell G, Tanguay R (2001) Tyrosinemia: a review. Pediatr Dev Pathol 4:212\u2013221","journal-title":"Pediatr Dev Pathol"},{"key":"15_CR47","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14656566.9.7.1229","volume":"9","author":"S Santra","year":"2008","unstructured":"Santra S, Baumann U (2008) Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 9:1229\u20131236","journal-title":"Expert Opin Pharmacother"},{"key":"15_CR48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI110809","volume":"71","author":"S Sassa","year":"1983","unstructured":"Sassa S, Kappas A (1983) Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71:625\u2013634","journal-title":"J Clin Invest"},{"issue":"Suppl. 2","key":"15_CR49","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1007\/s10545-008-0807-z","volume":"31","author":"JU Schlump","year":"2008","unstructured":"Schlump JU, Perot C, Ketteler K et al (2008) Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis 31(Suppl. 2):S223\u2013S225","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"15_CR50","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/pbc.25094","volume":"61","author":"J Seda Neto","year":"2014","unstructured":"Seda Neto J, Leite KM, Porta A et al (2014) HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1. Pediatr Blood Cancer 61(9):1584\u20131589","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"15_CR51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.rct.0000163179.10595.c4","volume":"29","author":"RN Sener","year":"2005","unstructured":"Sener RN (2005a) Tyrosinemia: computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain. J Comput Assist Tomogr 29(3):323\u2013325","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"15_CR52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/02841850510021517","volume":"46","author":"RN Sener","year":"2005","unstructured":"Sener RN (2005b) Brain magnetic resonance imaging in tyrosinemia. Acta Radiol 46(6):618\u2013620","journal-title":"Acta Radiol"},{"issue":"3","key":"15_CR53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4212\/cjhp.v68i3.1454","volume":"68","author":"M Simoncelli","year":"2015","unstructured":"Simoncelli M, Samson J, Bussi\u00e8res JF et al (2015) Cost-consequence analysis of nitisinone for treatment of tyrosinemia type I. Can J Hosp Pharm 68(3):210\u2013217","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"15_CR54","first-page":"308","volume":"47","author":"RM Tanguay","year":"1990","unstructured":"Tanguay RM, Valet JP, Lescault et al (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47(2):308\u2013316","journal-title":"Am J Hum Genet"},{"key":"15_CR55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-011-9394-5","volume":"35","author":"E Thimm","year":"2012","unstructured":"Thimm E, Richter-Werkle R, Kamp G et al (2012) Neurocognitive outcome in patients with hypertyrosinemia type 1 after long-term treatment with NTBC. J Inherit Metab Dis 35:263\u2013268. 43","journal-title":"J Inherit Metab Dis"},{"key":"15_CR56","unstructured":"Tuncbilek E, Ozguc M (2007) Application of medical genetics in Turkey. Turk J Pediatr 49:353\u2013359. 25"},{"issue":"3","key":"15_CR57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5152\/balkanmedj.2016.141074","volume":"33","author":"HK Ucar","year":"2016","unstructured":"Ucar HK, Tumgor G, Kor D et al (2016) A case report of very rare association of Tyrosinemia type I and pancreatitis mimicking neurologic crisis of Tyrosinemia type I. Balkan Med J 33(3):370\u2013372","journal-title":"Balkan Med J"},{"issue":"3","key":"15_CR58","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1542\/peds.2014-1913","volume":"135","author":"WG Ginkel van","year":"2015","unstructured":"van Ginkel WG, Gouw AS, van der Jagt EJ et al (2015) Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics 135(3):e749\u2013e752","journal-title":"Pediatrics"},{"issue":"5","key":"15_CR59","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","volume":"20","author":"FJ Spronsen van","year":"1994","unstructured":"van Spronsen FJ, Thomasse Y, Smit GP et al (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20(5):1187\u20131191","journal-title":"Hepatology"},{"key":"15_CR60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00005176-200501000-00017","volume":"40","author":"FJ Spronsen Van","year":"2005","unstructured":"Van Spronsen FJ, Bijleveld CM, Van Maldegem BT et al (2005) Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2nitro-4-3-trifluoro-methylbenzoyl)-1,3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 40:90\u201393","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"15_CR61","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.transproceed.2015.04.019","volume":"47","author":"MA Yagci","year":"2015","unstructured":"Yagci MA, Tardu A, Karagul S et al (2015) Living donor liver transplantation with vena cava replacement. Transplant Proc 47(5):1453\u20131457","journal-title":"Transplant Proc"},{"key":"15_CR62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.clinbiochem.2013.02.002","volume":"46","author":"TH Zytkovicz","year":"2013","unstructured":"Zytkovicz TH, Sahai I, Rush A et al (2013) Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program. Clin Biochem 46:681\u2013684","journal-title":"Clin Biochem"}],"container-title":["Advances in Experimental Medicine and Biology","Hereditary Tyrosinemia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-55780-9_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:38:12Z","timestamp":1750790292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-55780-9_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319557793","9783319557809"],"references-count":65,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-55780-9_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2017]]}}}